SynthesisOncotarget2016
Transforming growth factor-β1 polymorphisms and graft-versus-host disease risk: a meta-analysis.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Investigation of TGFB1 -1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2020Article
- Polymorphisms in the TGFB1 and IL2RA genes are associated with clinical forms of leprosy in Brazilian population.Memorias do Instituto Oswaldo Cruz · 2018Article
- Transforming growth factor-β1 functional polymorphisms in myeloablative sibling hematopoietic stem cell transplantation.Bone marrow transplantation · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Some studies have demonstrated that transforming growth factor (TGF)-β polymorphisms may have an important role in the pathological process of graft-versus-host disease (GVHD). However, the results are not consistent. Thus, we performed a meta-analysis. Online databases were searched to obtain relevant articles published up until May 2015. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations. Donors (OR=0.56; 95%CI, 0.32-0.98; P=0.04) and recipients (OR=0.73; 95%CI, 0.63-0.85; P<0.0001) with TGF-β1 rs1800469 polymorphism showed decreased GVHD risk, respectively. Donors with TGF-β1 rs1800470 polymorphism were also observed to have lower GVHD risk (OR=0.65; 95%CI, 0.46-0.94; P=0.02). However, TGF-β1 rs1800470 polymorphism in recipients was not associated with GVHD risk (OR=1.28; 95%CI, 0.81-2.01; P=0.29). No significant heterogeneity was found in the meta-analysis. This meta-analysis suggests that donors or recipients with TGF-β1 rs1800469 polymorphism and donors with TGF-β1 rs1800470 polymorphism might be associated with reduced GVHD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.